1 row is stored for this page
| Field | Field type | Value |
|---|
| generic | String | Rivaroxaban |
| brand | String | Xarelto |
| structure | File | |
| classes | List of String, delimiter: , | [[:Category:Anticoagulants|Anticoagulant]] • [[:Category:Direct_factor_Xa_inhibitors|Direct factor Xa inhibitor]] • [[:Category:DOACs|Direct oral anticoagulant (DOAC)]] |
| mechanism | String | '"`UNIQ--vote-0000050D-QINU`"' CYP3A4 (primary) and P-glycoprotein substrate; strong dual inhibitors or inducers materially shift exposure. Reversal: andexanet alfa for life-threatening bleeding; 4F-PCC commonly used off-label when andexanet unavailable'"`UNIQ--ref-0000050E-QINU`"'. |
| uses | String | '"`UNIQ--vote-0000050F-QINU`"', '"`UNIQ--vote-00000510-QINU`"', '"`UNIQ--vote-00000511-QINU`"', '"`UNIQ--vote-00000512-QINU`"' |
| starting_dose | String | NVAF: 20 mg PO once daily with the evening meal (15 mg if CrCl 15-50); acute VTE: 15 mg BID for 21 days, then 20 mg daily; CAD/PAD: 2.5 mg BID with aspirin |
| preparations | String | 2.5, 10, 15, 20 mg tablets |
| fda_max | String | 30 mg/d (acute VTE first 21 days as 15 mg BID); otherwise 20 mg/d |
| pill_id | Text | |
| routes | List of String, delimiter: , | Oral |
| onset | String | Peak anticoagulant effect 2-4 hours |
| duration | String | 24 hours |
| halflife | String | 5-9 hours (elderly: 11-13 hours)'"`UNIQ--ref-00000513-QINU`"' |
| bioavailability | String | ~80-100% with food at 15-20 mg doses (10 mg dose: ~80% without food); '''must be taken with food''' at therapeutic doses'"`UNIQ--ref-00000514-QINU`"' |
| pregnancy | String | Avoid in pregnancy; switch to LMWH. Crosses placenta; warfarin-class concerns about fetal hemorrhage and teratogenicity make heparins the preferred class.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> |
| legal | String | [[USLegal:Prescription only|Rx-only]] in US |
